In summary, these results indicated that combination treatment with a c-Myc inhibitor and an anti-PD-1 antibody exhibited a synergistic therapeutic effect in osteosarcoma that was dependent on CD4+ and CD8+ T cells. Here, CD8A is linked to osteosarcoma.